NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Abraham, Fruchter & Twersky, LLP (https://aftlaw.com/), a nationally recognized law firm that focuses on protecting investors' rights, is investigating whether Morphic Holding, Inc. (NASDAQ:MORF), a biopharmaceutical company, violated U.S. federal securities laws by making false or misleading statements or failing to timely disclose material information to investors.
On September 22, 2023, Morphic released data from its EMERALD-1 Phase 2a trial for its drug candidate, MORF-057, revealing that "endoscopic improvement was ...
MORF)>Full story available on Benzinga.com